Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis
Upadacitinib may be more effective than tofacitinib in achieving and sustaining SFCR, with better treatment persistence and similar overall safety. Larger, prospective head-to-head trials are needed to validate these findings.
Institutions
- AdventHealth Orlando (US)
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1159/000549088
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82